Anti-TIM-1 / KIM-1

0.5mg/ml if reconstituted with 0.2ml sterile DI water. TIM-1 antibody targets T cell immunoglobulin and mucin domain containing protein 1, also widely known as Kidney injury molecule 1 (KIM-1) and encoded by the HAVCR1 gene. TIM-1 is a type I transmembrane glycoprotein with an extracellular immunoglobulin V-like domain and a mucin-rich region, localized primarily to the plasma membrane. Under normal physiological conditions, TIM-1 expression in kidney tissue is low, but it is strongly induced in proximal tubular epithelial cells following renal injury, making it a well-established marker of kidney damage.Functionally, T cell immunoglobulin and mucin domain containing protein 1 participates in epithelial cell injury responses, phagocytosis of apoptotic debris, and immune modulation. TIM-1 has been shown to act as a scavenger receptor that recognizes phosphatidylserine on apoptotic cells, facilitating clearance and tissue repair processes. In immune cells, TIM-1 can influence T cell activation and cytokine production, linking tissue injury signals with immune regulation. A TIM-1 antibody supports studies focused on renal injury mechanisms and immune signaling.TIM-1 expression is most prominently associated with injured kidney epithelium, but it is also detected in activated immune cells, including subsets of T lymphocytes. Its inducible expression pattern reflects a role in sensing cellular stress and damage rather than maintaining baseline tissue function. TIM-1 can interact with multiple ligands and signaling partners, enabling it to participate in pathways that regulate inflammation, tissue remodeling, and immune responses following injury.From a disease-relevance perspective, TIM-1, also referred to as KIM-1, is extensively studied as a biomarker for acute kidney injury and chronic kidney disease. Elevated TIM-1 expression correlates with tubular damage and disease severity, and it has been investigated in toxicological studies, ischemia-reperfusion injury, and drug-induced nephrotoxicity. Beyond renal disease, TIM-1 has also been explored in inflammatory disorders and cancer biology, where its immune regulatory functions may contribute to disease progression.At the molecular level, T cell immunoglobulin and mucin domain containing protein 1 contains conserved structural domains that support ligand binding and signal transduction. Glycosylation of the mucin domain can influence apparent migration behavior on SDS-PAGE without implying changes in primary sequence. TIM-1 antibody reagents support research applications focused on kidney injury, epithelial stress responses, and immune regulation, with NSJ Bioreagents providing reagents intended for research use.